Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reducing ARIA risk in Alzheimer's disease: Real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab.

Journal of Alzheimer's disease : JAD - 1 Oct 2025

Mervosh Nicholas, Bilici Nadir, Wisniewski Thomas, Devi Gayatri

Abstract excerpt

We evaluated whether apolipoprotein E (APOE) genotype-guided slow titration of monoclonal antibodies reduced amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease. We retrospectively analyzed ARIA incidence in 25 patients on aducanumab and 19 patients on lecanemab on a genotype-informed protocol in a private practice setting. ARIA-E and ARIA-H each occurred in 4% of the aducanumab group and 5% of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Antibodies, Monoclonal, Humanized

Share to Apolipoproteins E

Share to APOE gene

Share to Genotype

Share to Plaque, Amyloid

Source

Identifiers

PMID: 40801838
DOI: 10.1177/13872877251366657

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reducing ARIA risk in Alzheimer's disease: Real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab.PMID 40801838Read ↗

Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health SystemSemantic proximity Read ↗

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read ↗

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read ↗

Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain WestSemantic proximity Read ↗

APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-β.Semantic proximity Read ↗

Relationship between APOE Genotype Status and Imaging Features in Patients with Alzheimer Disease Being Considered for Antiamyloid β Therapy.Semantic proximity Read ↗

Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical PracticeSemantic proximity Read ↗

Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain.Semantic proximity Read ↗

Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era.Semantic proximity Read ↗

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialSemantic proximity Read ↗

Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brainSemantic proximity Read ↗

Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.